ASCO CAR-T Highlights: Exploring New Frontiers For The Field

As Novartis awaits word from FDA on its CTL019, company trumpets potential of its "next-generation" CAR-T therapy CTL119 in combination with Imbruvica, with data from a small pilot study being presented at ASCO.